Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic MSCs for Radiation-induced Xerostomia
NCT03874572Phase 1Active, not recruiting
- Sponsor
- Rigshospitalet
- Start
- Mar 2019
- Primary completion
- Jun 2020
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CSCC_ASC in radiation-induced xerostomia and hyposalivation, sponsored by Rigshospitalet. Primary endpoint: Number of patients with serious adverse events at 4 months. Started Mar 2019; status: active, not recruiting.
02
Drugs
CSCC_ASC
03
Conditions
radiation-induced xerostomiahyposalivation
Beyond the preview
Go deeper on NCT03874572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03874572.